Literature DB >> 11972873

The cell biology of MHC class I antigen presentation.

A Williams1, C A Peh, T Elliott.   

Abstract

MHC class I antigen presentation refers to the co-ordinated activities of many intracellular pathways that promote the cell surface appearance of MHC class I/beta2m heterodimers loaded with a spectrum of self or foreign peptides. These MHC class I peptide complexes form ligands for CD8 positive T cells and NK cells. MHC class I heterodimers are loaded within the endoplasmic reticulum (ER) with peptides derived from intracellular proteins. Alternatively, MHC class I molecules may be loaded with peptides derived from extracellular proteins in a process called MHC class I cross presentation. This pathway is less well defined but can overlap those pathways operating in classical MHC class I presentation and has recently been reviewed elsewhere (1). This review will address the current concepts regarding the intracellular assembly of MHC class I molecules with their peptide cargo within the ER and their subsequent progress to the cell surface.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11972873     DOI: 10.1034/j.1399-0039.2002.590103.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  35 in total

1.  Short class I major histocompatibility complex cytoplasmic tails differing in charge detect arbiters of lateral diffusion in the plasma membrane.

Authors:  G George Capps; Samuel Pine; Michael Edidin; Martha C Zúñiga
Journal:  Biophys J       Date:  2004-05       Impact factor: 4.033

2.  Model for the interaction of gammaherpesvirus 68 RING-CH finger protein mK3 with major histocompatibility complex class I and the peptide-loading complex.

Authors:  Xiaoli Wang; Lonnie Lybarger; Rose Connors; Michael R Harris; Ted H Hansen
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

3.  Requirements for the selective degradation of endoplasmic reticulum-resident major histocompatibility complex class I proteins by the viral immune evasion molecule mK3.

Authors:  Xiaoli Wang; Rose Connors; Michael R Harris; Ted H Hansen; Lonnie Lybarger
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Bap31 enhances the endoplasmic reticulum export and quality control of human class I MHC molecules.

Authors:  John J Ladasky; Sarah Boyle; Malini Seth; Hewang Li; Tsvetelina Pentcheva; Fumiyoshi Abe; Steven J Steinberg; Michael Edidin
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

Review 5.  Advances in the immunobiology and treatment of inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

6.  Cloning and functional analyses of the mouse tapasin promoter.

Authors:  Felix Herrmann; John Trowsdale; Christoph Huber; Barbara Seliger
Journal:  Immunogenetics       Date:  2003-08-26       Impact factor: 2.846

7.  Equine herpesvirus type 4 UL56 and UL49.5 proteins downregulate cell surface major histocompatibility complex class I expression independently of each other.

Authors:  Abdelrahman Said; Walid Azab; Armando Damiani; Nikolaus Osterrieder
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

8.  Human self-protein CD8+ T-cell epitopes are both positively and negatively selected.

Authors:  Michal Almani; Shai Raffaeli; Tal Vider-Shalit; Lea Tsaban; Vered Fishbain; Yoram Louzoun
Journal:  Eur J Immunol       Date:  2009-04       Impact factor: 5.532

9.  Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection.

Authors:  Shirin Ashraf; Katja Nitschke; Usama M Warshow; Collin R Brooks; Arthur Y Kim; Georg M Lauer; Theresa J Hydes; Matthew E Cramp; Graeme Alexander; Ann-Margaret Little; Robert Thimme; Christoph Neumann-Haefelin; Salim I Khakoo
Journal:  Hepatology       Date:  2013-07-29       Impact factor: 17.425

10.  Beta2-microglobulin-dependent bacterial clearance and survival during murine Klebsiella pneumoniae bacteremia.

Authors:  Anna L Cogen; Thomas A Moore
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.